背景:本研究之目的在估計鎝-99m也trofosmin腫瘤的攝取與p-醣蛋白及多藥物抗藥性相關蛋白在乳癌表見之相關性O方法:利用免疫組織化學分析法來決定20位乳癌病患p-醣蛋白及多藥物抗藥性相關蛋白之表現。根據免疫組織化學分析法，比20位乳癌病息被分為兩群:(A) 10位腫瘤病人具有p-醣蛋白及多藥物抗藥性相關蛋白的表現; (B) 10位腫瘤病 人沒有p-醣蛋白及多藥物抗藥性相關蛋白的表現。此20位乳3屆病患皆先接受鎝-99m-tetrofosmin乳房閃爍造影以計算其種瘤/背景比值。

結果:在這兩群病人中，A群病人的腫瘤/背景比值(1.1S±0.1O)明顯低於B群病人(2.19±O.lS) (P

Purpose: The aim of this study was to evaluate the relationship between the tumor uptake of technetium- 99m-tetrofosmin ("9mTc_ TF) and the expressions of Pglycoprotein (Pgp) and multidrug resistance related protein (MRP) in breast cancers.

Methods: Determination of Pgp and MRP expressions were performed by immunohistochemical analyses (IHA) on biopsy or surgery specimens of the 20 breast cancers. According to the results of IHA， the 20 breast cancers were separated into 2 groups: (A) 10 tumors with positive MRP and Pgp expressions， and (B) 10 tumors with negative MRP and Pgp expressions. All of the 20 patients underwent 99mTc-TF mammoscintigraphy to calculate tumor to background (T/B) ratios on breast cancers before IHA and biopsy/surgery

Results: Between the 2 groups， the T/B ratios were significantly lower in group A (1.15 ± 0.10) than in group B (2.19 ± 0.15) (P<0.001).

Conclusion: Our results indicate that 99mTc-TF mammoscintigraphy is helpful for predicting of Pgp and MRP expressions in breast cancers.